Figure 7

WFA inhibits bone turnover and has direct effect on osteoblast-specific genes in femurs of OVx mice. (a) Serum OCN levels as measured at the end of experiment from various treatment groups. Data show that WFA inhibits bone turnover in OVx mice. All values are expressed as mean±S.E.M. *P<0.05, **P<0.01, ***P<0.001 compared with OVx group. ^aP<0.001 when 10 mg/kg/day dose was compared with 1 mg/kg/day dose, ^eP<0.01 when 10 mg/kg/day dose compared with 5 mg/kg/day dose. (b) Circulating TNFα levels from serum of various groups were measured by ELISA at the end of the experiment period. All values are expressed as mean±S.E. of three independent experiments (n=3). **P<0.01 compared with OVx group. (c) Direct effect of WFA at the end of experiment on long bones (femur). Data show qPCR of osteogenic genes RunX2, ColI and OCN in RNA isolated from bone. All values are expressed as mean±S.E. of three independent experiments (n=3). *P<0.05, **P<0.01, ***P<0.001 compared with OVx group. ^aP<0.001 when 10 mg/kg/day dose was compared with 1 mg/kg/day dose, ^bP<0.01 when 10 mg/kg/day dose compared with 1 mg/kg/day dose, ^dP<0.001 when 10 mg/kg/day dose compared with 5 mg/kg/day dose, ^eP<0.01 when 10 mg/kg/day dose compared with 5 mg/kg/day dose, ^gP<0.05 when 10 mg/kg/day dose compared with Ald 3 mg/kg/day dose, ^hP<0.01 when 10 mg/kg/day dose compared with PTH mg/kg/day dose, ⁱP<0.05 when 10 mg/kg/day dose compared with Bzb 0.3 mg/kg/day dose for RunX2 gene expression. (d) Effect of WFA on mRNA expression of Smurf2 in femur at the end of experimental period. All values are expressed as mean±S.E.M. of three independent experiments (n=3). *P<0.05, **P<0.01, ***P<0.001 when compared with OVx group, ^bP<0.01 when 10 mg/kg/day dose was compared with 1 mg/kg/day dose, ⁱP<0.05 when 10 mg/kg/day dose compared with Bzb 0.3 mg/kg/day dose